Aquestive Therapeutics (AQST) Invested Capital: 2017-2025
Historic Invested Capital for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $2.2 million.
- Aquestive Therapeutics' Invested Capital rose 628.10% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 628.10%. This contributed to the annual value of -$15.2 million for FY2024, which is 75.35% up from last year.
- Per Aquestive Therapeutics' latest filing, its Invested Capital stood at $2.2 million for Q3 2025, which was up 103.20% from -$69.4 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Invested Capital registered a high of $9.5 million during Q2 2024, and its lowest value of -$98.3 million during Q3 2023.
- Over the past 3 years, Aquestive Therapeutics' median Invested Capital value was -$60.9 million (recorded in 2025), while the average stood at -$42.3 million.
- The largest annual percentage gain for Aquestive Therapeutics' Invested Capital in the last 5 years was 628.10% (2025), contrasted with its biggest fall of 829.05% (2025).
- Over the past 5 years, Aquestive Therapeutics' Invested Capital (Quarterly) stood at -$80.1 million in 2021, then rose by 16.30% to -$67.1 million in 2022, then increased by 8.30% to -$61.5 million in 2023, then spiked by 75.35% to -$15.2 million in 2024, then spiked by 628.10% to $2.2 million in 2025.
- Its Invested Capital was $2.2 million in Q3 2025, compared to -$69.4 million in Q2 2025 and -$60.9 million in Q1 2025.